BioMed Target Journal. 2023, 1(1):2-11
https://doi.org/10.59786/bmtj.112

BIOMED TARGET JOURNAL

Review Article

Unleashing the Power of OpenAI in Shaping the Future of Cancer Research

Ramyar M. Abdullah [1], Hawro D. I. Masseh[2] Abbas Salihi [3,*] Mohammed Faraj[4]

[1]Erbil Directorate of Health, Erbil, Kurdistan Region, Iraq
[2]Department of Medical Laboratory Technology, Erbil Technical Health and Medical College, Erbil Polytechnic University, Kurdistan Region, Iraq
[3]Department of Biology, College of Science, Salahaddin University-Erbil, 44001, Kurdistan Region, Iraq
[4]Department of Computer Science, College of Science, University of Halabja, 46018, Iraq

*** Correspondence**
abbas.salihi@su.edu.krd

Article Info
Received: May 1, 2023
Revised: May 31, 2023
Accepted: June 6, 2023

Abstract

Artificial intelligence (AI) is rapidly changing cancer research and treatment development. OpenAI, a pioneer in AI research, is at the vanguard of this revolution. This review article highlights the potential of OpenAI to shape the future of cancer research, including the identification of new therapeutic targets, predictive modeling for cancer progression and response to therapy, the development of personalized treatment plans, and advancements in drug discovery and development. The article also discusses the challenges of implementing OpenAI in cancer research and incorporating AI into the research process. Finally, the article concludes with a discussion of AI's future prospects in cancer research, as well as future research recommendations.

Keywords: Open AI, Cancer Research.

INTRODUCTION

Artificial intelligence has emerged as a promising tool in cancer research, opening up new avenues for furthering our understanding of this complex disease[1]. OpenAI, a leading research institute dedicated to the advancement of AI technology, has been critical in harnessing the power of AI to address the many challenges that cancer researchers face today[2]. In this review, we will look at the impact of OpenAI on the future of cancer research, focusing on recent advances and current challenges.

AI has been used in a variety of cancer research applications in recent years, from identifying new therapeutic targets to developing predictive models for cancer progression and response to therapy[3]. AI can also accelerate the identification of novel medication candidates and improve pre-clinical and clinical studies[4]. Despite these exciting developments, there are significant challenges associated with integrating AI into the cancer research process, such as ethical concerns about data privacy and security, as well as the need to validate AI predictions and address data bias issues[5]. In this review article, we will explore these and other key themes in AI and cancer research, drawing on the most recent research and best practices. Our goal is to provide a thorough overview of OpenAI's role in shaping the future of cancer research, as well as insights into the potential benefits and limitations of AI technology in this critical field. OpenAI is a non-profit AI research laboratory comprised of the for-profit technological firm OpenAI LP and its non-profit parent company, OpenAI Inc. Elon Musk, Sam Altman, Greg Brockman, Ilya Sutskever, Wojciech Zaremba, and John Schulman founded it in 2015 to promote and develop friendly AI that benefits humanity. The goal of OpenAI is to create safe AI systems that learn how to solve problems and advance scientific discovery for the benefit of all. The organization conducts research in a variety of fields, including natural language processing, robotics, and machine learning, and it has made numerous significant contributions to the AI community.



Figure 1. The importance of AI in cancer therapy and research

Artificial intelligence has emerged as a powerful tool in cancer research, with the potential to transform the field in a variety of ways. The importance of AI in cancer research stems from its ability to analyze massive amounts of complex data, identify patterns and insights that humans would be unable to detect and improve the accuracy and efficiency of various diagnostic and treatment methods.

The ability of AI to analyze considerable patient data sets, including genomics, clinical records, and lifestyle factors, to identify personalized treatment options for each patient is one of the technology's most important contributions to the field of cancer research[6]. By providing individualized treatments that are more efficient and have fewer side effects, this strategy, also known as precision medicine, can help improve patient outcomes[7] (Figure 1). AI can also help identify potential drug targets and design new molecules with desired properties. This can significantly reduce the time and cost of developing new drugs, allowing new treatments to reach the market more quickly[8]. Additionally, AI has the potential to increase the precision of various diagnostic techniques, including pathology and medical imaging, by detecting subtle changes that human eyes may miss. This can aid in cancer detection and diagnosis, resulting in better treatment outcomes[9-12].

The article could provide a rigorous analysis of the field's current state and identify key areas for future research. It will also provide researchers, practitioners, and policymakers with practical recommendations to help optimize the use of OpenAI in cancer research. The purpose of this

article is to provide readers with a clear and concise overview of the role that OpenAI can play in shaping the future of cancer research, as well as a better understanding of the potential benefits and limitations of this cutting-edge technology.

I. Advancements in cancer research through OpenAI

The platform provided by OpenAI for scientists to analyze enormous amounts of complex data, find patterns and insights, and create new treatments and therapies has the potential to revolutionize cancer research[13]. OpenAI can help quicken the pace of discovery and the introduction of new treatments to the market by utilizing the strength of machine learning algorithms[14,15]. The existence of individualized treatment plans for cancer patients is one area where OpenAI is significantly advancing research[16,17]. OpenAI can find treatment options that are specifically suited to the needs of each patient by analyzing huge datasets of patient data, including genomic data, lifestyle factors, and clinical records[18]. Precision medicine is an approach that aims to provide more efficient and targeted treatments for patients, potentially improving patient outcomes[19].

Medical imaging and pathology are two additional diagnostic techniques that can benefit from increased accuracy and speed thanks to OpenAI[20]. OpenAI can diagnose cancer earlier and with greater accuracy by analyzing images and other diagnostic data using machine learning algorithms to identify subtle changes that human observers might miss[21-23]. Furthermore, by identifying potential drug targets and designing new molecules with desired properties, OpenAI can help speed up the drug discovery process[24]. This can significantly reduce the time and cost of developing new drugs, allowing new treatments to reach the market more quickly.

A. Identification of new therapeutic targets using AI

The discovery of new therapeutic targets is a critical step in the development of cancer drugs, and OpenAI is playing an increasingly important role in this process[25,26]. OpenAI can identify potential drug targets that traditional methods may have missed by analyzing large datasets of genomic and molecular data[27]. Machine learning algorithms can assist in identifying specific genes or proteins linked to cancer development and progression, as well as potential molecular pathways that drugs can target[28,29]. OpenAI can also involve the development of new drugs that specifically target these pathways, increasing the likelihood of clinical trial success[30]. This approach has already yielded promising results in the development of cancer treatments, and as technology advances, it has the potential to revolutionize how we discover and develop new cancer therapies[31,32].

B. Predictive modelling for cancer progression and response to therapy

Another area where OpenAI is making significant progress in cancer research is predictive modeling[16]. Machine learning algorithms can identify patterns and correlations in large datasets of patient data to help predict how a patient's cancer will progress and how they will respond to different treatments[33-36]. This can help clinicians make more informed decisions about treatment options, potentially improving outcomes and saving lives[37,38]. OpenAI can also make it easier to identify patients who are at a higher risk of developing cancer or who may benefit more from certain preventive measures[16,39]. As the amount of patient data grows, the potential for AI to improve predictive modelling in cancer research is enormous, and it has the potential to revolutionize the way we diagnose and treat cancer[40-43].

II. The future of cancer research with OpenAI

With the integration of OpenAI technology, the future of cancer research appears bright[2,44]. OpenAI has the potential to revolutionize cancer research by providing advanced machine learning and AI tools that can be used to analyze complex data and identify patterns that humans alone may not be able to detect[45,46]. OpenAI's ability to process massive amounts of data quickly and accurately can assist researchers in identifying new biomarkers for cancer, developing more effective treatments, and improving patient outcomes[47,48]. Cancer researchers can use OpenAI to accelerate discovery, reduce time and costs associated with

traditional research methods, and ultimately improve our understanding of this complex disease[49]. Furthermore, OpenAI can aid in the development of personalized treatment plans that are tailored to each patient's unique genetic makeup, resulting in better outcomes and a higher quality of life[50]. As OpenAI evolves, its potential applications in cancer research will only grow, making it an indispensable tool for researchers in their quest to find a cure[16].

A. Development of personalized cancer treatment plans

In recent years, the development of personalized cancer treatment plans has revolutionized cancer treatment[51]. Individual patient characteristics such as genetic makeup, lifestyle, and medical history are taken into account in personalized treatment plans, allowing healthcare professionals to tailor treatment options to each patient's unique needs[7,52]. This method has shown promise in terms of improving cancer treatment outcomes while reducing the risk of adverse side effects[53].

The use of advanced technologies such as AI and machine learning (ML) algorithms is one of the key drivers of personalized cancer treatment plans[54]. These technologies can analyze large amounts of patient data to identify patterns and predict treatment outcomes[55]. Researchers, for example, have used machine learning to analyze genetic data from cancer patients and predict which treatments are most likely to be effective based on the patient's specific genetic mutations[28,56-58]. Similarly, machine learning algorithms have been used to identify patients who are at high risk of experiencing severe side effects from certain treatments, allowing clinicians to adjust treatment plans accordingly[59,60].

The accuracy of cancer diagnosis could be increased with the help of personalized cancer treatment plans, enabling earlier detection and better treatment options[61]. Healthcare professionals can prevent the disease from progressing to advanced stages by analyzing patient data and spotting early warning signs of cancer[62-64].

A significant advancement in cancer research and treatment is the creation of personalized cancer treatment plans[65]. Healthcare professionals can better tailor treatment options to each patient's individual needs by utilizing cutting-edge technologies like AI and ML, which will improve outcomes and reduce the possibility of negative side effects. The future of personalized cancer treatment appears more promising than ever as these technologies advance[66].

B. Increased efficiency and accuracy in data analysis

A major goal in cancer research is to improve the efficiency and accuracy of data analysis[67,68]. AI is playing an important role in this area by automating the analysis of large amounts of data, reducing the time and effort required to identify patterns and correlations[68,69]. To determine the best treatment plan, OpenAI employs AI algorithms to analyze patient data such as medical history, genetics, and treatment history. This method enables the rapid analysis of large amounts of data, reducing the time and effort required for data analysis.

AI algorithms can improve the accuracy of data analysis in addition to increasing its efficiency. AI algorithms can detect patterns and correlations that human analysts may miss, resulting in more accurate predictions and better decision-making[70]. Finally, increased efficiency and accuracy in data analysis is an important goal in cancer research, and OpenAI is at the forefront of using AI to achieve this goal[71]. OpenAI is helping to improve the efficiency and accuracy of data analysis by automating the analysis of large amounts of data, resulting in better patient outcomes and lower costs[72].

C. Advancements in drug discovery and development through AI

Artificial intelligence has transformed drug discovery and development by allowing researchers to sift through massive amounts of data, identify patterns, and make predictions with unprecedented accuracy. The use of AI in drug discovery has significantly reduced the time and cost of developing new drugs, making it a critical

tool in the fight against diseases[73]. One of the most significant advantages of AI in drug discovery is its ability to analyze large amounts of data from various sources, such as genomics, proteomics, and metabolomics[74]. This data can be sifted through by AI algorithms to identify potential targets for new drugs, predict the efficacy of drug candidates, and optimize drug properties to increase their chances of success.

Machine learning is another way in which AI is transforming drug development. Machine learning algorithms can learn from previous drug development successes and failures, allowing them to predict which compounds will succeed in clinical trials. This reduces the time and resources needed to develop new drugs while increasing clinical trial success rates[75]. Furthermore, AI is also being used in the development of personalized medicine. By analyzing patients' genetic and clinical data, AI algorithms can identify individuals who are most likely to benefit from a particular drug, reducing the risk of adverse reactions and improving treatment outcomes[76]. To summarize, the integration of AI in drug discovery and development has significantly improved the efficiency, accuracy, and speed of drug development. The ability of AI algorithms to analyze large amounts of data, predict drug efficacy, and optimize drug properties has transformed the drug development process, resulting in the development of new treatments and therapies for a variety of diseases.

III. Challenges in implementing OpenAI in cancer research

Although OpenAI has enormous potential in cancer research, several challenges must be overcome before it can be effectively implemented. One of the most significant challenges is a lack of high-quality data. While there is a massive amount of cancer-related data available, much of it is scattered across multiple databases and is frequently incomplete, making it difficult to use for training machine learning algorithms[16,77]. Another challenge is the complexities of cancer biology. Cancer is a multifaceted disease with multiple genetic and molecular pathways, making it difficult to identify specific targets for drug development. Furthermore, cancer cells can mutate and evolve, making accurate prediction difficult[78,79].

The use of AI in cancer research raises ethical concerns. The use of AI to predict patient outcomes, for example, could result in discrimination or bias against specific groups. It is critical to ensure that AI algorithms are transparent and unbiased, as well as that patient privacy is protected[80]. To fully realize the potential of OpenAI in cancer research, interdisciplinary collaboration between computer scientists, data scientists, and cancer researchers is required. This collaboration necessitates the use of a common language as well as an understanding of each discipline's strengths and weaknesses.

A. Integration of AI into the research process

The incorporation of AI into the research process has the potential to change the way we approach scientific inquiry. AI can analyze large datasets, identify patterns, and make predictions that humans would find difficult or impossible to detect. AI can also develop and test hypotheses, design experiments, and even write scientific papers[81]. The use of automated laboratory equipment is one way that AI is being integrated into the research process. These systems can run experiments faster and more accurately than humans, allowing researchers to collect large amounts of data in a short period. The data can then be analyzed by AI algorithms to identify patterns and generate new hypotheses[82].

The development of predictive models is another way that AI is being used in the research process. These models can be trained on large datasets to predict a wide range of phenomena, from molecule behaviour to disease spread[83]. AI is also being used to improve clinical trial efficiency. AI can help researchers design more effective trials and identify patients who are most likely to benefit from a particular treatment by analyzing patient data and predicting outcomes[84].

However, incorporating AI into the research process is not without its difficulties. The need for high-quality data is one of the biggest obstacles. To produce precise predictions and insights, AI algorithms rely on vast amounts of high-quality

data. In addition, there are ethical issues with AI use in research, such as protecting patient privacy and avoiding bias and discrimination[85]. In conclusion, incorporating AI into the research process has the potential to revolutionize the field of science. AI can assist researchers in making discoveries and enhancing patient outcomes by analyzing sizable datasets, developing, and testing hypotheses, and enhancing the effectiveness of clinical trials. To make sure that AI is used effectively and ethically, it is crucial to address the issues related to its use in research.

B. Validation of AI predictions in the lab

The lab validation of AI predictions is a critical step in ensuring the accuracy and reliability of AI-generated insights. While AI algorithms can be used to analyze large datasets and make predictions, the validity of these predictions must be confirmed through experimentation[81,86]. The use of automated laboratory equipment to perform experiments based on predictions is one approach to validating AI predictions in the lab. This enables researchers to test the predictions generated by AI algorithms quickly and accurately, identifying any discrepancies or errors[87].

Another approach is to use AI-generated predictions to guide the design of experiments. By incorporating AI predictions into the experimental design process, researchers can develop more targeted and efficient experiments, reducing the time and resources required for validation[88,89]. To ensure generalizability, AI predictions must be validated across multiple datasets and experimental conditions. Data quality, experimental design, and statistical significance must all be carefully considered. Validation of AI predictions in the lab is critical for ensuring the accuracy and reliability of AI-generated insights. Researchers can ensure that AI-generated insights are robust and scientifically sound by using automated laboratory equipment, incorporating AI predictions into experimental design, and validating predictions across multiple datasets and experimental conditions[90,91].

C. Ethical considerations in the use of AI for cancer research

The use of AI in cancer research has the potential to revolutionize the field, but it also raises significant ethical concerns that must be addressed. One of the main ethical concerns is ensuring that AI is used in a fair and unbiased manner. This includes making certain that AI algorithms are trained on diverse datasets that accurately reflect the populations being studied, and that the data used is not biased towards specific groups or demographics[92,93]. Another ethical consideration is the privacy of patients. Large amounts of patient data are required for AI algorithms to generate accurate predictions and insights. This data must be collected, stored, and used in a manner that protects patient privacy and complies with applicable regulations and laws[94].

Transparency and accountability are also critical ethical considerations when using AI in cancer research. Researchers must be open about the algorithms and data they use in their research, and they must accept responsibility for any biases or errors that are discovered[95,96]. The use of AI in cancer research raises concerns about the role of humans in the research process. While AI can generate and analyze large amounts of data, it is critical to incorporate human expertise and judgment into the research process[97]. In conclusion, the application of AI to the study of cancer presents exciting prospects for novel insights and enhanced patient outcomes. To ensure that AI is used ethically and effectively in the pursuit of cancer research, it is crucial to carefully consider and address ethical issues like fairness, privacy, transparency, accountability, and human involvement.

Conclusions

AI has a promising future in cancer research. AI has the potential to accelerate cancer research and improve patient outcomes as machine learning algorithms and big data analytics improve. One area of focus is personalized medicine, in which AI can analyze a patient's genetic and clinical data to develop tailored treatment plans. Furthermore, AI can help identify new drug targets and predict drug responses, potentially leading to more effective therapies. AI can also help in the early detection of

cancer, increasing the chances of successful treatment. Several challenges, however, must be addressed, including data privacy, algorithm transparency, and ethical considerations. Despite these obstacles, the incorporation of AI into cancer research is expected to grow and expand in the coming years, eventually leading to improved cancer prevention, diagnosis, and treatment.

Conflict of Interest

The authors declare they have no conflicting interests.

REFERENCES

1. Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial Intelligence in Cancer Research and Precision Medicine. *Cancer Discov*. Apr 2021;11(4):900-915. doi:10.1158/2159-8290.CD-21-0090
2. Sebastian AM, Peter D. Artificial Intelligence in Cancer Research: Trends, Challenges and Future Directions. *Life (Basel)*. Nov 28 2022;12(12)doi:10.3390/life12121991
3. Gawehn E, Hiss JA, Schneider G. Deep Learning in Drug Discovery. *Molecular informatics*. Jan 2016;35(1):3-14. doi:10.1002/minf.201501008
4. Szegedy C, Wei L, Yangqing J, et al. Going deeper with convolutions. 2015:1-9.
5. Murdoch B. Privacy and artificial intelligence: challenges for protecting health information in a new era. *BMC Medical Ethics*. 2021/09/15 2021;22(1):122. doi:10.1186/s12910-021-00687-3
6. Johnson KB, Wei WQ, Weeraratne D, et al. Precision Medicine, AI, and the Future of Personalized Health Care. *Clinical and translational science*. Jan 2021;14(1):86-93. doi:10.1111/cts.12884
7. Schork NJ. Artificial Intelligence and Personalized Medicine. *Cancer treatment and research*. 2019;178:265-283. doi:10.1007/978-3-030-16391-4_11
8. Sarkar C, Das B, Rawat VS, et al. Artificial Intelligence and Machine Learning Technology Driven Modern Drug Discovery and Development. *International Journal of Molecular Sciences*. 2023;24(3):2026.
9. Koh DM, Papanikolaou N, Bick U, et al. Artificial intelligence and machine learning in cancer imaging. *Commun Med (Lond)*. 2022;2:133. doi:10.1038/s43856-022-00199-0
10. Kumar Y, Gupta S, Singla R, Hu YC. A Systematic Review of Artificial Intelligence Techniques in Cancer Prediction and Diagnosis. *Arch Comput Methods Eng*. 2022;29(4):2043-2070. doi:10.1007/s11831-021-09648-
11. Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts H. Artificial intelligence in radiology. *Nat Rev Cancer*. Aug 2018;18(8):500-510. doi:10.1038/s41568-018-0016-5
12. Lee LIT, Kanthasamy S, Ayyalaraju RS, Ganatra R. The Current State of Artificial Intelligence in Medical Imaging and Nuclear Medicine. *BJR open*. 2019;1(1):20190037. doi:10.1259/bjro.20190037
13. Jungwirth D, Haluza D. Artificial Intelligence and Public Health: An Exploratory Study. *International Journal of Environmental Research and Public Health*. 2023;20(5):4541.
14. Liu Z, Roberts RA, Lal-Nag M, Chen X, Huang R, Tong W. AI-based language models powering drug discovery and development. *Drug discovery today*. 2021/11/01/ 2021;26(11):2593-2607. doi:https://doi.org/10.1016/j.drudis.2021.06.009
15. Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer. *JAMA*. 2017;318(22):2199-2210. doi:10.1001/jama.2017.14585
16. Sebastian AM, Peter D. Artificial Intelligence in Cancer Research: Trends, Challenges and Future Directions. *Life*. 2022;12(12):1991.
17. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. *Nature Medicine*. 2019/01/01 2019;25(1):24-29. doi:10.1038/s41591-018-0316-z
18. Acosta JN, Falcone GJ, Rajpurkar P, Topol EJ. Multimodal biomedical AI. *Nature Medicine*. 2022/09/01 2022;28(9):1773-1784. doi:10.1038/s41591-022-01981-2
19. Dolsten M, Søgaard M. Precision medicine: an approach to R&D for delivering superior medicines to patients. *Clin Transl Med*. May 30 2012;1(1):7. doi:10.1186/2001-1326-1-7
20. Al-Antari MA. Artificial Intelligence for Medical Diagnostics—Existing and Future AI Technology! *Diagnostics*. 2023;13(4):688.
21. Rösler W, Altenbuchinger M, Baeßler B, et al. An overview and a roadmap for artificial intelligence in hematology and oncology. *Journal of Cancer Research and Clinical Oncology*. 2023/03/15 2023;doi:10.1007/s00432-023-04667-5
22. Albahra S, Gorbett T, Robertson S, et al. Artificial intelligence and machine learning overview in pathology & laboratory medicine: A general review of data preprocessing and basic supervised concepts. *Seminars in Diagnostic Pathology*. 2023/03/01/ 2023;40(2):71-87. doi:https://doi.org/10.1053/j.semdp.2023.02.002
23. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. *Future healthcare journal*. Jun 2019;6(2):94-98. doi:10.7861/futurehosp.6-2-94
24. Bittner MI, Farajnia S. AI in drug discovery: Applications, opportunities, and challenges. *Patterns (New York, NY)*. Jun 10 2022;3(6):100529. doi:10.1016/j.patter.2022.100529
25. Wang L, Song Y, Wang H, et al. Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade. *Pharmaceuticals*. 2023;16(2):253.
26. Kifle ZD, Tadele M, Alemu E, Gedamu T, Ayele AG. A recent development of new therapeutic agents and novel drug targets for cancer treatment. *SAGE open medicine*. 2021;9:20503121211067083.

27. Caudai C, Galizia A, Geraci F, et al. AI applications in functional genomics. *Comput Struct Biotechnol J*. 2021;19:5762-5790. doi:10.1016/j.csbj.2021.10.009
28. Habibi M, Taheri G. A new machine learning method for cancer mutation analysis. *PLoS computational biology*. Oct 2022;18(10):e1010332. doi:10.1371/journal.pcbi.1010332
29. You Y, Lai X, Pan Y, et al. Artificial intelligence in cancer target identification and drug discovery. *Signal Transduction and Targeted Therapy*. 2022/05/10 2022;7(1):156. doi:10.1038/s41392-022-00994-0
30. Liu Z, Roberts RA, Lal-Nag M, Chen X, Huang R, Tong W. AI-based language models powering drug discovery and development. *Drug discovery today*. Nov 2021;26(11):2593-2607. doi:10.1016/j.drudis.2021.06.009
31. Ando K, Hu Q, Kasagi Y, Oki E, Mori M. Recent developments in cancer research: Expectations for a new remedy. *Ann Gastroenterol Surg*. Jul 2021;5(4):419-426. doi:10.1002/ags3.12440
32. Ching T, Himmelstein DS, Beaulieu-Jones BK, et al. Opportunities and obstacles for deep learning in biology and medicine. *Journal of The Royal Society Interface*. 2018;15(141):20170387. doi:doi:10.1098/rsif.2017.0387
33. Kourou K, Exarchos KP, Papaloukas C, Sakaloglou P, Exarchos T, Fotiadis DI. Applied machine learning in cancer research: A systematic review for patient diagnosis, classification and prognosis. *Comput Struct Biotechnol J*. 2021;19:5546-5555. doi:10.1016/j.csbj.2021.10.006
34. Cruz JA, Wishart DS. Applications of machine learning in cancer prediction and prognosis. *Cancer informatics*. Feb 11 2007;2:59-77.
35. Rafique R, Islam SMR, Kazi JU. Machine learning in the prediction of cancer therapy. *Computational and Structural Biotechnology Journal*. 2021/01/01/ 2021;19:4003-4017. doi:https://doi.org/10.1016/j.csbj.2021.07.003
36. Tran KA, Kondrashova O, Bradley A, Williams ED, Pearson JV, Waddell N. Deep learning in cancer diagnosis, prognosis and treatment selection. *Genome Medicine*. 2021/09/27 2021;13(1):152. doi:10.1186/s13073-021-00968-x
37. Zeng L, Liu L, Chen D, et al. The innovative model based on artificial intelligence algorithms to predict recurrence risk of patients with postoperative breast cancer. *Front Oncol*. 2023;13:1117420. doi:10.3389/fonc.2023.1117420
38. Jungwirth D, Haluza D. Artificial Intelligence and Public Health: An Exploratory Study. *Int J Environ Res Public Health*. Mar 3 2023;20(5)doi:10.3390/ijerph20054541
39. Johnson SB, King AJ, Warner EL, Aneja S, Kann BH, Bylund CL. Using ChatGPT to evaluate cancer myths and misconceptions: artificial intelligence and cancer information. *JNCI Cancer Spectr*. Mar 1 2023;7(2)doi:10.1093/jncics/pkad015
40. Farina E, Nabhen JJ, Dacoregio MI, Batalini F, Moraes FY. An overview of artificial intelligence in oncology. *Future science OA*. Apr 2022;8(4):Fso787. doi:10.2144/fsoa-2021-0074
41. Jacob T. Shreve M, Sadia A. Khanani M, Tufia C. Haddad M. Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical Considerations. *American Society of Clinical Oncology Educational Book*. 2022;(42):842-851. doi:10.1200/edbk_350652
42. Shao D, Dai Y, Li N, et al. Artificial intelligence in clinical research of cancers. *Briefings in Bioinformatics*. 2021;23(1)doi:10.1093/bib/bbab523
43. Lin B, Tan Z, Mo Y, Yang X, Liu Y, Xu B. Intelligent oncology: The convergence of artificial intelligence and oncology. *Journal of the National Cancer Center*. 2023/03/01/ 2023;3(1):83-91. doi:https://doi.org/10.1016/j.jncc.2022.11.004
44. Cabral BP, Braga LAM, Syed-Abdul S, Mota FB. Future of Artificial Intelligence Applications in Cancer Care: A Global Cross-Sectional Survey of Researchers. *Current Oncology*. 2023;30(3):3432-3446.
45. Shimizu H, Nakayama KI. Artificial intelligence in oncology. *Cancer Sci*. May 2020;111(5):1452-1460. doi:10.1111/cas.14377
46. Chen M, Decary M. Artificial intelligence in healthcare: An essential guide for health leaders. *Healthcare Management Forum*. 2020;33(1):10-18. doi:10.1177/0840470419873123
47. Liao J, Li X, Gan Y, et al. Artificial intelligence assists precision medicine in cancer treatment. *Front Oncol*. 2022;12:998222. doi:10.3389/fonc.2022.998222
48. Shao D, Dai Y, Li N, et al. Artificial intelligence in clinical research of cancers. *Brief Bioinform*. Jan 17 2022;23(1)doi:10.1093/bib/bbab523
49. Ren F, Ding X, Zheng M, et al. AlphaFold accelerates artificial intelligence powered drug discovery: efficient discovery of a novel CDK20 small molecule inhibitor. *Chemical Science*. 2023;14(6):1443-1452. doi:10.1039/D2SC05709C
50. Haluza D, Jungwirth D. Artificial Intelligence and Ten Societal Megatrends: An Exploratory Study Using GPT-3. *Systems*. 2023;11(3):120.
51. Gambardella V, Tarazona N, Cejalvo JM, et al. Personalized Medicine: Recent Progress in Cancer Therapy. *Cancers (Basel)*. Apr 19 2020;12(4)doi:10.3390/cancers12041009
52. Goetz LH, Schork NJ. Personalized medicine: motivation, challenges, and progress. *Fertility and sterility*. Jun 2018;109(6):952-963. doi:10.1016/j.fertnstert.2018.05.006
53. Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. *Oncotarget*. Jun 6 2017;8(23):38022-38043. doi:10.18632/oncotarget.16723
54. Koh D-M, Papanikolaou N, Bick U, et al. Artificial intelligence and machine learning in cancer imaging. *Communications Medicine*. 2022/10/27 2022;2(1):133. doi:10.1038/s43856-022-00199-0

55. Sahu M, Gupta R, Ambasta RK, Kumar P. Artificial intelligence and machine learning in precision medicine: A paradigm shift in big data analysis. *Progress in molecular biology and translational science*. 2022;190(1):57-100. doi:10.1016/bs.pmbts.2022.03.002
56. Malebary SJ, Khan YD. Evaluating machine learning methodologies for identification of cancer driver genes. *Scientific Reports*. 2021/06/10 2021;11(1):12281. doi:10.1038/s41598-021-91656-8
57. Nguyen L, Van Hoeck A, Cuppen E. Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features. *Nature Communications*. 2022/07/11 2022;13(1):4013. doi:10.1038/s41467-022-31666-w
58. Dlamini Z, Skepu A, Kim N, et al. AI and precision oncology in clinical cancer genomics: From prevention to targeted cancer therapies-an outcomes based patient care. *Informatics in Medicine Unlocked*. 2022/01/01/ 2022;31:100965. doi:https://doi.org/10.1016/j.imu.2022.100965
59. Habehh H, Gohel S. Machine Learning in Healthcare. *Current genomics*. Dec 16 2021;22(4):291-300. doi:10.2174/1389202922666210705124359
60. Javaid M, Haleem A, Pratap Singh R, Suman R, Rab S. Significance of machine learning in healthcare: Features, pillars and applications. *International Journal of Intelligent Networks*. 2022/01/01/ 2022;3:58-73. doi:https://doi.org/10.1016/j.ijin.2022.05.002
61. Grandori C, Kemp CJ. Personalized Cancer Models for Target Discovery and Precision Medicine. *Trends in cancer*. Sep 2018;4(9):634-642. doi:10.1016/j.trecan.2018.07.005
62. Karger E, Kureljusic M. Artificial Intelligence for Cancer Detection-A Bibliometric Analysis and Avenues for Future Research. *Curr Oncol*. Jan 29 2023;30(2):1626-1647. doi:10.3390/curroncol30020125
63. Torrente M, Sousa PA, Hernández R, et al. An Artificial Intelligence-Based Tool for Data Analysis and Prognosis in Cancer Patients: Results from the Clarify Study. *Cancers (Basel)*. Aug 22 2022;14(16)doi:10.3390/cancers14164041
64. Dlamini Z, Francies FZ, Hull R, Marima R. Artificial intelligence (AI) and big data in cancer and precision oncology. *Computational and Structural Biotechnology Journal*. 2020/01/01/ 2020;18:2300-2311. doi:https://doi.org/10.1016/j.csbj.2020.08.019
65. Hoeben A, Joosten EAJ, van den Beuken-van Everdingen MHJ. Personalized Medicine: Recent Progress in Cancer Therapy. *Cancers (Basel)*. Jan 11 2021;13(2)doi:10.3390/cancers13020242
66. Lin PC, Tsai YS, Yeh YM, Shen MR. Cutting-Edge AI Technologies Meet Precision Medicine to Improve Cancer Care. *Biomolecules*. Aug 17 2022;12(8)doi:10.3390/biom12081133
67. Xu W, Huang SH, Su J, Gudi S, O'Sullivan B. Statistical fundamentals on cancer research for clinicians: Working with your statisticians. *Clinical and translational radiation oncology*. Mar 2021;27:75-84. doi:10.1016/j.ctro.2021.01.006
68. Nath AS, Pal A, Mukhopadhyay S, Mondal KC. A survey on cancer prediction and detection with data analysis. *Innovations in Systems and Software Engineering*. 2020/12/01 2020;16(3):231-243. doi:10.1007/s11334-019-00350-6
69. Jiang P, Sinha S, Aldape K, Hannenhalli S, Sahinalp C, Ruppin E. Big data in basic and translational cancer research. *Nature Reviews Cancer*. 2022/11/01 2022;22(11):625-639. doi:10.1038/s41568-022-00502-0
70. Sarker IH. AI-Based Modeling: Techniques, Applications and Research Issues Towards Automation, Intelligent and Smart Systems. *SN Computer Science*. 2022/02/10 2022;3(2):158. doi:10.1007/s42979-022-01043-x
71. Holzinger A, Keiblinger K, Holub P, Zatloukal K, Müller H. AI for life: Trends in artificial intelligence for biotechnology. *New Biotechnology*. 2023/05/25/ 2023;74:16-24. doi:https://doi.org/10.1016/j.nbt.2023.02.001
72. Dave M, Patel N. Artificial intelligence in healthcare and education. *British Dental Journal*. 2023/05/01 2023;234(10):761-764. doi:10.1038/s41415-023-5845-2
73. Farghali H, Kutinová Canová N, Arora M. The potential applications of artificial intelligence in drug discovery and development. *Physiological research*. Dec 30 2021;70(Suppl4):S715-s722. doi:10.33549/physiolres.934765
74. Dara S, Dhamercherla S, Jadav SS, Babu CM, Ahsan MJ. Machine Learning in Drug Discovery: A Review. *Artificial intelligence review*. 2022;55(3):1947-1999. doi:10.1007/s10462-021-10058-4
75. Patel V, Shah M. Artificial intelligence and machine learning in drug discovery and development. *Intelligent Medicine*. 2022/08/01/ 2022;2(3):134-140. doi:https://doi.org/10.1016/j.imed.2021.10.001
76. Gallo C. Artificial Intelligence for Personalized Genetics and New Drug Development: Benefits and Cautions. *Bioengineering*. 2023;10(5):613.
77. Sweeney SM, Hamadeh HK, Abrams N, et al. Case Studies for Overcoming Challenges in Using Big Data in Cancer. *Cancer research*. Apr 14 2023;83(8):1183-1190. doi:10.1158/0008-5472.can-22-1277
78. Karimi MR, Karimi AH, Abolmaali S, Sadeghi M, Schmitz U. Prospects and challenges of cancer systems medicine: from genes to disease networks. *Briefings in bioinformatics*. Jan 17 2022;23(1)doi:10.1093/bib/bbab343
79. Upadhyay A. Cancer: An unknown territory; rethinking before going ahead. *Genes & diseases*. Sep 2021;8(5):655-661. doi:10.1016/j.gendis.2020.09.002
80. Belenguer L. AI bias: exploring discriminatory algorithmic decision-making models and the application of possible machine-centric solutions adapted from the pharmaceutical industry. *AI and Ethics*. 2022/11/01 2022;2(4):771-787. doi:10.1007/s43681-022-00138-8

81. Xu Y, Liu X, Cao X, et al. Artificial intelligence: A powerful paradigm for scientific research. *The Innovation*. 2021/11/28/ 2021;2(4):100179. doi:https://doi.org/10.1016/j.xinn.2021.100179
82. Lee D, Yoon SN. Application of Artificial Intelligence-Based Technologies in the Healthcare Industry: Opportunities and Challenges. *International journal of environmental research and public health*. Jan 1 2021;18(1)doi:10.3390/ijerph18010271
83. Santangelo OE, Gentile V, Pizzo S, Giordano D, Cedrone F. Machine Learning and Prediction of Infectious Diseases: A Systematic Review. *Machine Learning and Knowledge Extraction*. 2023;5(1):175-198.
84. Weissler EH, Naumann T, Andersson T, et al. The role of machine learning in clinical research: transforming the future of evidence generation. *Trials*. 2021/08/16 2021;22(1):537. doi:10.1186/s13063-021-05489-x
85. Perifanis N-A, Kitsios F. Investigating the Influence of Artificial Intelligence on Business Value in the Digital Era of Strategy: A Literature Review. *Information*. 2023;14(2):85.
86. Tran TTV, Tayara H, Chong KT. Artificial Intelligence in Drug Metabolism and Excretion Prediction: Recent Advances, Challenges, and Future Perspectives. *Pharmaceutics*. 2023;15(4):1260.
87. Undru TR, Uday U, Lakshmi JT, et al. Integrating Artificial Intelligence for Clinical and Laboratory Diagnosis - a Review. *Maedica*. Jun 2022;17(2):420-426. doi:10.26574/maedica.2022.17.2.420
88. Xu Y, Liu X, Cao X, et al. Artificial intelligence: A powerful paradigm for scientific research. *Innovation (Cambridge (Mass))*. Nov 28 2021;2(4):100179. doi:10.1016/j.xinn.2021.100179
89. Linardatos P, Papastefanopoulos V, Kotsiantis S. Explainable AI: A Review of Machine Learning Interpretability Methods. *Entropy*. 2021;23(1):18.
90. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. *Medical oncology (Northwood, London, England)*. Jun 15 2022;39(8):120. doi:10.1007/s12032-022-01711-1
91. Lavin A, Gilligan-Lee CM, Visnjic A, et al. Technology readiness levels for machine learning systems. *Nature Communications*. 2022/10/20 2022;13(1):6039. doi:10.1038/s41467-022-33128-9
92. Naik N, Hameed BMZ, Shetty DK, et al. Legal and Ethical Consideration in Artificial Intelligence in Healthcare: Who Takes Responsibility? *Frontiers in surgery*. 2022;9:862322. doi:10.3389/fsurg.2022.862322
93. Akinci D'Antonoli T. Ethical considerations for artificial intelligence: an overview of the current radiology landscape. *Diagnostic and interventional radiology (Ankara, Turkey)*. Sep 2020;26(5):504-511. doi:10.5152/dir.2020.19279
94. Gerke S, Minssen T, Cohen G. *Ethical and legal challenges of artificial intelligence-driven healthcare*. Artificial Intelligence in Healthcare. 2020:295-336. doi: 10.1016/B978-0-12-818438-7.00012-5. Epub 2020 Jun 26.
95. Zhang J, Zhang ZM. Ethics and governance of trustworthy medical artificial intelligence. *BMC medical informatics and decision making*. Jan 13 2023;23(1):7. doi:10.1186/s12911-023-02103-9
96. Li F, Ruijs N, Lu Y. Ethics & AI: A Systematic Review on Ethical Concerns and Related Strategies for Designing with AI in Healthcare. *AI*. 2023;4(1):28-53.
97. Bi WL, Hosny A, Schabath MB, et al. Artificial intelligence in cancer imaging: Clinical challenges and applications. *CA: a cancer journal for clinicians*. Mar 2019;69(2):127-157. doi:10.3322/caac.21552